References

Comprehensive multi-omics approach reveals critical genes and immunometabolic networks in glioblastoma

10.1097/js9.0000000000002634 · 2025 · External reference

Brain immunology and immunotherapy in brain tumours

10.1038/s41568-019-0224-7 · 2020 · External reference

Glioblastoma multiforme (GBM): an overview of current therapies and mechanisms of resistance

10.1016/j.phrs.2021.105780 · 2021 · External reference

Advancing glioblastoma therapy: learning from the past and innovations for the future

10.1016/j.canlet.2025.217601 · 2025 · External reference

EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood

10.1038/s41571-020-00447-z · 2021 · External reference

Targeting the glioblastoma resection margin with locoregional nanotechnologies

10.1038/s41571-025-01020-2 · 2025 · External reference

Supramarginal resection of glioblastoma: a review[J]

10.1016/j.nec.2024.08.007 · 2024 · External reference

Glioblastoma in adults: a society for neuro-oncology (SNO) and European Society of Neuro-oncology (EANO) consensus review on current management and future directions

10.1093/neuonc/noaa106 · 2020 · External reference

Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma

10.1093/annonc/mdx169 · 2017 · External reference

Recurrence pattern analysis of primary glioblastoma

10.1016/j.wneu.2017.04.053 · 2017 · External reference

Targeting therapeutic nanoparticles to the glioblastoma resection margin by harnessing postoperative blood-brain barrier disruption

10.1126/scitranslmed.adv8761 · 2026 · External reference

The dynamics of tumor-infiltrating myeloid cell activation and the cytokine expression profile in a glioma resection site during the post-surgical period in mice

10.3390/brainsci12070893 · 2022 · External reference

Interrogation of the microenvironmental landscape in brain tumors reveals disease-specific alterations of immune cells

10.1016/j.cell.2020.05.007 · 2020 · External reference

Single-cell transcriptomic analysis of glioblastoma reveals pericytes contributing to the blood-brain-tumor barrier and tumor progression

2024 · External reference

CRISPR/Cas9-induced knockout reveals the role of ABCB1 in the response to temozolomide, carmustine and lomustine in glioblastoma multiforme

10.1016/j.phrs.2022.106510 · 2022 · External reference

Single-cell dissection of the human blood-brain barrier and glioma blood-tumor barrier

10.1016/j.neuron.2024.07.026 · 2024 · External reference

Tailoring glioblastoma treatment based on longitudinal analysis of post-surgical tumor microenvironment

10.1186/s13046-024-03231-4 · 2024 · External reference

Construction of a whole-brain panorama for glioma vasculature reveals tumor heterogeneity and blood-brain barrier disruption

10.1126/sciadv.adw8330 · 2025 · External reference

Dual-responsive nanoparticle system for enhanced blood-brain barrier crossing and glioblastoma penetration

10.1016/j.biomaterials.2025.123730 · 2026 · External reference

Reprogramming systemic and local immune function to empower immunotherapy against glioblastoma

10.1038/s41467-023-35957-8 · 2023 · External reference

A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma

10.1093/neuonc/5.2.79 · 2003 · External reference

Biomarkers and smart intracranial devices for the diagnosis, treatment, and monitoring of high-grade gliomas: a review of the literature and future prospects

2019 · External reference

Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results

10.1200/jco.1998.16.6.2202 · 1998 · External reference

Multifunctional hybrid hydrogel system enhanced the therapeutic efficacy of treatments for postoperative glioma

10.1021/acsami.2c05147 · 2022 · External reference

Stimulation of tumoricidal immunity via bacteriotherapy inhibits glioblastoma relapse

10.1038/s41467-024-48606-5 · 2024 · External reference

Neural stem cell-delivered oncolytic virus via intracerebroventricular administration enhances glioblastoma therapy and immune modulation

10.1136/jitc-2025-012934 · 2025 · External reference

Postoperative injection of a triptolide-preloaded hydrogel prevents the recurrence of glioblastoma by dual-pathway activation of ferroptosis

10.1002/smll.202406036 · 2024 · External reference

Developing implantable scaffolds to enhance neural stem cell therapy for post-operative glioblastoma

10.1016/j.ymthe.2020.02.008 · 2020 · External reference

Biodegradable nanofibrous scaffolds enhance standard of care for glioblastoma via localized targeted therapy

10.1016/j.jconrel.2025.114225 · 2025 · External reference

Glioblastoma cell adhesion properties through bacterial cellulose nanocrystals in polycaprolactone/gelatin electrospun nanofibers

10.1016/j.carbpol.2019.115820 · 2020 · External reference

3D-printed implants loaded with acriflavine for glioblastoma treatment

10.1016/j.ijpharm.2024.124710 · 2024 · External reference

Implantable microneedle-mediated eradication of postoperative tumor foci mitigates glioblastoma relapse

10.1002/adma.202409857 · 2024 · External reference

Self-oxygenating PROTAC microneedle for spatiotemporally-confined protein degradation and enhanced glioblastoma therapy

10.1002/adma.202411869 · 2025 · External reference

Silk microneedle patch capable of on-demand multidrug delivery to the brain for glioblastoma treatment

2022 · External reference

Spatiotemporal tracking of gold nanorods after intranasal administration for brain targeting

10.1016/j.jconrel.2023.04.022 · 2023 · External reference

A microfluidics-based scalable approach to generate extracellular vesicles with enhanced therapeutic microRNA loading for intranasal delivery to mouse glioblastomas

10.1021/acsnano.1c07587 · 2021 · External reference

Multiplexed epigenetic memory editing using CRISPRoff sensitizes glioblastoma to chemotherapy

10.1093/neuonc/noaf055 · 2025 · External reference

Hyaluronan decorated layer-by-layer assembled lipid nanoparticles for miR-181a delivery in glioblastoma treatment

10.1016/j.biomaterials.2023.122341 · 2023 · External reference

CD47 knock-out using CRISPRI-Cas9 RNA lipid nanocarriers results in reduced mesenchymal glioblastoma growth in vivo

2025 · External reference

Bio-polymeric transferrin-targeted temozolomide nanoparticles in gel for synergistic post-surgical GBM therapy

10.1039/d2nr00171c · 2022 · External reference

Inorganic and hybrid nanomaterials for NIR-II fluorescence imaging-guided therapy of glioblastoma and perspectives

10.7150/thno.112204 · 2025 · External reference

TREM2 mediates MHCII-associated CD4+ T-cell response against gliomas

10.1093/neuonc/noad214 · 2024 · External reference

Dual avβ8 integrin and PD-1 blockade overcomes TGFβ-mediated B-cell suppression to enhance anti-tumor immunity

10.1093/neuonc/noaf106 · 2025 · External reference

Emerging extracellular vesicle-based carriers for glioblastoma diagnosis and therapy

10.1039/d3nr01667f · 2023 · External reference

Glioblastoma at the crossroads: current understanding and future therapeutic horizons

10.1038/s41392-025-02299-4 · 2025 · External reference

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

10.1056/nejmoa043330 · 2005 · External reference

Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial

10.1001/jama.2017.18718 · 2017 · External reference

The 2021 WHO classification of tumors of the central nervous system: a summary

10.1093/neuonc/noab106 · 2021 · External reference

MGMT gene silencing and benefit from temozolomide in glioblastoma

10.1056/nejmoa043331 · 2005 · External reference

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

10.1200/jco.2008.19.8721 · 2009 · External reference

Lomustine and bevacizumab in progressive glioblastoma

10.1056/nejmoa1707358 · 2017 · External reference

RAGE inhibitors as alternatives to dexamethasone for managing cerebral edema following brain tumor surgery

10.1007/s13311-022-01207-w · 2022 · External reference

Surgical resection of glioblastomas induces pleiotrophin-mediated self-renewal of glioblastoma stem cells in recurrent tumors

10.1093/neuonc/noab302 · 2022 · External reference

Shared inflammatory glial cell signature after stab wound injury, revealed by spatial, temporal, and cell-type-specific profiling of the murine cerebral cortex

10.1038/s41467-024-46625-w · 2024 · External reference

Surgical debulking promotes recruitment of macrophages and triggers glioblastoma phagocytosis in combination with CD47 blocking immunotherapy

10.18632/oncotarget.14553 · 2017 · External reference

Mesoscale recovery of microglial and neuronal dynamics after craniotomy across wide cortex in transgenic mice

2026 · External reference

Limited recurrence distance of glioblastoma under modern radiotherapy era

10.1186/s12885-021-08467-3 · 2021 · External reference

Brain invasion along perivascular spaces by glioma cells: relationship with blood-brain barrier

10.3390/cancers12010018 · 2019 · External reference

Precancerous cells initiate glioblastoma evolution and contribute to intratumoral heterogeneity

10.1158/2159-8290.cd-24-0234 · 2025 · External reference

Glioblastoma evolution and heterogeneity from a 3D whole-tumor perspective

10.1016/j.cell.2023.12.013 · 2024 · External reference

Cancer stem cell hypothesis 2.0 in glioblastoma: where are we now and where are we going?

10.1093/neuonc/noae011 · 2024 · External reference

Characterisation of the tumour microenvironment in primary and recurrent glioblastomas

10.1111/nan.13012 · 2024 · External reference

CD103+ regulatory T cells underlie resistance to radio-immunotherapy and impair CD8+ T cell activation in glioblastoma

2023 · External reference

Single-cell transcriptomics reveals immunosuppressive microenvironment and highlights tumor-promoting macrophage cells in glioblastoma

10.1371/journal.pone.0312764 · 2025 · External reference

Localized treatment of glioblastoma: a review of clinical strategies and advances in drug delivery systems

10.1080/17435889.2025.2550239 · 2025 · External reference

IGFBP5 is an ROR1 ligand promoting glioblastoma invasion via ROR1/HER2-CREB signaling axis

10.1038/s41467-023-37306-1 · 2023 · External reference

Local therapeutic platform prevents postsurgical GBM recurrence by diminishing GICs and reshaping immunosuppressive microenvironment

10.1038/s41467-025-67415-y · 2025 · External reference

The invasion phenotypes of glioblastoma depend on plastic and reprogrammable cell states

10.1038/s41467-025-61999-1 · 2025 · External reference

Mechanisms regulating glioma invasion

10.1016/j.canlet.2015.03.015 · 2015 · External reference

Recent development of contrast agents for magnetic resonance and multimodal imaging of glioblastoma

10.1186/s12951-022-01479-6 · 2022 · External reference

Preoperative PET imaging and fluorescence-guided surgery of human glioblastoma using dual-labeled antibody targeting ET(A) receptors in a preclinical mouse model: a theranostic approach

10.7150/thno.98163 · 2024 · External reference

Irdye800cw labeled upar-targeting peptide for fluorescence-guided glioblastoma surgery: preclinical studies in orthotopic xenografts

10.7150/thno.49787 · 2021 · External reference

First-in-human study of pet and optical dual-modality image-guided surgery in glioblastoma using (68)Ga-IRDye800CW-BBN

10.7150/thno.25599 · 2018 · External reference

Residual tumor cells are unique cellular targets in glioblastoma

10.1002/ana.22036 · 2010 · External reference

Surgical results of tumor resection using tractography-integrated navigation-guided fence-post catheter techniques and motor-evoked potentials for preservation of motor function in patients with glioblastomas near the pyramidal tracts

10.1007/s10143-014-0593-z · 2015 · External reference

Integrative multi-omics analysis reveal novel therapeutic targets for glioblastoma

10.1097/js9.0000000000002941 · 2025 · External reference

The somatic genomic landscape of glioblastoma

10.1016/j.cell.2013.09.034 · 2013 · External reference

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

10.1016/j.ccr.2009.12.020 · 2010 · External reference

EPHA2 mediates PDGFA activity and functions together with PDGFRA as prognostic marker and therapeutic target in glioblastoma

10.1038/s41392-021-00855-2 · 2022 · External reference

Endothelial-secreted endocan activates PDGFRA and regulates vascularity and spatial phenotype in glioblastoma

10.1038/s41467-024-55487-1 · 2025 · External reference

Cancer cell heterogeneity and plasticity: a paradigm shift in glioblastoma

10.1093/neuonc/noab269 · 2022 · External reference

Integrated single-cell transcriptomic analyses reveal that GPNMB-high macrophages promote PN-MES transition and impede T cell activation in GBM

10.1016/j.ebiom.2022.104239 · 2022 · External reference

Integrative analysis identifies an immune-relevant epigenetic signature for prognostication of non-G-CIMP glioblastomas

10.1080/2162402x.2021.1902071 · 2021 · External reference

Genome-wide methylation profiling identifies an essential role of reactive oxygen species in pediatric glioblastoma multiforme and validates a methylome specific for H3 histone family 3A with absence of G-CIMP/isocitrate dehydrogenase 1 mutation

10.1093/neuonc/nou113 · 2014 · External reference

Role of N6-methyladenosine methylation in glioma: recent insights and future directions

10.1186/s11658-023-00514-0 · 2023 · External reference

m6A modification in rna: biogenesis, functions and roles in gliomas

10.1186/s13046-020-01706-8 · 2020 · External reference

O-GlcNAcylation stabilized WTAP promotes GBM malignant progression in an N6-methyladenosine-dependent manner

10.1093/neuonc/noae268 · 2025 · External reference

Metabolic regulation of the glioblastoma stem cell epitranscriptome by malate dehydrogenase 2

10.1016/j.cmet.2024.09.014 · 2024 · External reference

Hypoxia-induced neuronal activity in glioma patients polarizes microglia by potentiating RNA m6A demethylation

10.1158/1078-0432.ccr-23-0430 · 2024 · External reference

Glioblastoma cortical organoids recapitulate cell-state heterogeneity and intercellular transfer

10.1158/2159-8290.cd-23-1336 · 2025 · External reference

The development and potent antitumor efficacy of CD44/CD133 dual-targeting IL7Rα-armored CAR-T cells against glioblastoma

10.1016/j.canlet.2025.217541 · 2025 · External reference

The rational development of CD133-targeting immunotherapies for glioblastoma

10.1016/j.stem.2020.04.008 · 2020 · External reference

Reprogramming transcription factors Oct4 and Sox2 induce a BRD-dependent immunosuppressive transcriptome in GBM-propagating cells

10.1158/0008-5472.can-20-2489 · 2021 · External reference

Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells

10.1016/j.cell.2014.02.030 · 2014 · External reference

HIF1α/ATF3 partake in PGK1 k191/k192 succinylation by modulating p4ha1/succinate signaling in glioblastoma

10.1093/neuonc/noae040 · 2024 · External reference

Hypoxia-driven protease legumain promotes immunosuppression in glioblastoma

2023 · External reference

Hypoxia-induced complement component 3 promotes aggressive tumor growth in the glioblastoma microenvironment

10.1172/jci.insight.179854 · 2024 · External reference

Hypoxia-induced TGFBI maintains glioma stem cells by stabilizing EPHA2

10.7150/thno.95141 · 2024 · External reference

STAT3 blockade inhibits radiation-induced malignant progression in glioma

10.1158/0008-5472.can-14-3331 · 2015 · External reference

Temozolomide promotes glioblastoma stemness expression through senescence-associated reprogramming via HIF1α/HIF2α regulation

10.1038/s41419-025-07617-w · 2025 · External reference

Glioma stem cells remodel immunotolerant microenvironment in GBM and are associated with therapeutic advancements

10.3233/cbm-230486 · 2024 · External reference

NOTCH -induced MDSC recruitment after oHSV virotherapy in CNS cancer models modulates antitumor immunotherapy

10.1158/1078-0432.ccr-21-2347 · 2022 · External reference

β2-microglobulin maintains glioblastoma stem cells and induces M2-like polarization of tumor-associated macrophages

10.1158/0008-5472.can-22-0507 · 2022 · External reference

IL-13Rα2/TGF-β bispecific CAR-T cells counter TGF-β-mediated immune suppression and potentiate anti-tumor responses in glioblastoma

10.1093/neuonc/noae126 · 2024 · External reference

Multi-scale signaling and tumor evolution in high-grade gliomas

10.1016/j.ccell.2024.06.004 · 2024 · External reference

Aberrant STAT3 signaling by Interleukin-4 in malignant glioma cells: involvement of IL-13Rα2

10.1158/0008-5472.can-04-3592 · 2005 · External reference

CSF-1R inhibition alters macrophage polarization and blocks glioma progression

10.1038/nm.3337 · 2013 · External reference

Antigen presentation by tumor-associated macrophages drives T cells from a progenitor exhaustion state to terminal exhaustion

10.1016/j.immuni.2024.11.026 · 2025 · External reference

Endothelial cells induce cancer stem cell features in differentiated glioblastoma cells via bFGF

10.1186/s12943-015-0420-3 · 2015 · External reference

Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma

10.1023/a:1023367223575 · 2003 · External reference

Cancer cell autophagy, reprogrammed macrophages, and remodeled vasculature in glioblastoma triggers tumor immunity

10.1016/j.ccell.2022.08.014 · 2022 · External reference

Fibrotic response to anti-CSF-1R therapy potentiates glioblastoma recurrence

10.1016/j.ccell.2024.08.012 · 2024 · External reference

Reactive astrocytes potentiate tumor aggressiveness in a murine glioma resection and recurrence model

10.1093/neuonc/now117 · 2016 · External reference

Modulation of the blood-brain barrier permeability by patient-derived glioblastoma stem cell secretome

10.1038/s41598-025-21272-3 · 2025 · External reference

Altered abundance of barrier-related proteins in brain microvascular endothelial cells of the GL261 mouse model of glioblastoma

10.1021/acs.molpharmaceut.5c00609 · 2025 · External reference

Cells of the blood-brain barrier: an overview of the neurovascular unit in health and disease

10.1007/978-1-0716-2289-6_1 · 2022 · External reference

Fixed-point cleaved bioinspired nanosystem via promoting LAT1-mediated BBB penetration for spatiotemporal therapy in TMZ resistant glioblastoma

10.1016/j.cej.2025.164470 · 2025 · External reference

Temozolomide competes for P-glycoprotein and contributes to chemoresistance in glioblastoma cells

10.1016/j.canlet.2015.07.013 · 2015 · External reference

Surface functionalized albumin nanoparticles of palbociclib with amplified brain delivery for treating brain glioblastoma

10.1038/s41598-025-13721-w · 2025 · External reference

Advances in brain-targeted delivery strategies and natural product-mediated enhancement of blood-brain barrier permeability

10.1186/s12951-025-03415-w · 2025 · External reference

P450 oxidoreductase regulates barrier maturation by mediating retinoic acid metabolism in a model of the human BBB

10.1016/j.stemcr.2022.07.010 · 2022 · External reference

The blood-brain barrier: bottleneck in brain drug development

10.1602/neurorx.2.1.3 · 2005 · External reference

The blood-brain barrier: structure, regulation, and drug delivery

10.1038/s41392-023-01481-w · 2023 · External reference

Enhancement of therapies for glioblastoma (gbm) using nanoparticle-based delivery systems

10.1208/s12249-021-01928-9 · 2021 · External reference

Key molecular alterations in endothelial cells in human glioblastoma uncovered through single-cell RNA sequencing

10.1172/jci.insight.150861 · 2021 · External reference

Angiogenic signaling pathways and anti-angiogenic therapy for cancer

10.1038/s41392-023-01460-1 · 2023 · External reference

Optical blood-brain-tumor barrier modulation expands therapeutic options for glioblastoma treatment

10.1038/s41467-023-40579-1 · 2023 · External reference

Microglia contributes to BAF-312 effects on blood-brain barrier stability

10.3390/biom12091174 · 2022 · External reference

Blood-brain barrier permeability increases with the differentiation of glioblastoma cells in vitro

10.1186/s12987-024-00590-0 · 2024 · External reference

The impact of P-glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors

10.1002/ijc.31052 · 2018 · External reference

Nanotherapeutic treatment of the invasive glioblastoma tumor microenvironment

10.1016/j.addr.2022.114415 · 2022 · External reference

Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial

10.1200/jco.2004.06.082 · 2004 · External reference

NRG oncology/RTOG1205: a randomized phase II trial of concurrent bevacizumab and reirradiation versus bevacizumab alone as treatment for recurrent glioblastoma

10.1200/jco.22.00164 · 2023 · External reference

LncRNA-mediated TPI1 and PKM2 promote self-renewal and chemoresistance in GBM

2024 · External reference

Cellular senescence-associated gene IFI16 promotes HMOX1-dependent evasion of ferroptosis and radioresistance in glioblastoma

10.1038/s41467-025-56456-y · 2025 · External reference

Lactylation-driven USP4-mediated ANXA2 stabilization and activation promotes maintenance and radioresistance of glioblastoma stem cells

10.1038/s41418-025-01494-8 · 2025 · External reference

SDC1-dependent TGM2 determines radiosensitivity in glioblastoma by coordinating EPG5-mediated fusion of autophagosomes with lysosomes

10.1080/15548627.2022.2105562 · 2023 · External reference

Rbbp4 regulates the expression of the mre11-rad50-nbs1 (mrn) complex and promotes DNA double-strand break repair to mediate glioblastoma chemoradiotherapy resistance

10.1016/j.canlet.2023.216078 · 2023 · External reference

SP1 upregulation bolsters the radioresistance of glioblastoma cells by promoting double strand breaks repair

10.3390/ijms241310658 · 2023 · External reference

Aberrant ATM signaling and homology-directed DNA repair as a vulnerability of p53-mutant GBM to azd1390-mediated radiosensitization

10.1126/scitranslmed.adj5962 · 2024 · External reference

Radioresistance and transcriptional reprograming of invasive glioblastoma cells

10.1016/j.ijrobp.2021.09.017 · 2021 · External reference

Selective inhibition of parallel DNA damage response pathways optimizes radiosensitization of glioblastoma stem-like cells

10.1158/0008-5472.can-14-3790 · 2015 · External reference

Cancer stem cells and glioblastoma: time for innovative biomarkers of radio-resistance?

10.3390/biology12101295 · 2023 · External reference

Dynamic changes in glioma macrophage populations after radiotherapy reveal CSF-1R inhibition as a strategy to overcome resistance

10.1126/scitranslmed.aaw7843 · 2020 · External reference

Colony stimulating factor 1 receptor inhibition delays recurrence of glioblastoma after radiation by altering myeloid cell recruitment and polarization

10.1093/neuonc/nov272 · 2015 · External reference

Resistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-β

10.1158/0008-5472.can-12-0546 · 2012 · External reference

Suppression of ITPKB degradation by TRIM25 confers TMZ resistance in glioblastoma through ROS homeostasis

10.1038/s41392-024-01763-x · 2024 · External reference

Overcoming temozolomide resistance in glioma: recent advances and mechanistic insights

10.1186/s40478-025-02046-4 · 2025 · External reference

Mechanisms and therapeutic implications of hypermutation in gliomas

10.1038/s41586-020-2209-9 · 2020 · External reference

MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance

10.1158/1078-0432.ccr-08-3012 · 2009 · External reference

Adaptive chromatin remodeling drives glioblastoma stem cell plasticity and drug tolerance

10.1016/j.stem.2016.11.003 · 2017 · External reference

An integrative model of cellular states, plasticity, and genetics for glioblastoma

10.1016/j.cell.2019.06.024 · 2019 · External reference

A single-cell atlas of glioblastoma evolution under therapy reveals cell-intrinsic and cell-extrinsic therapeutic targets

2022 · External reference

CCAAT/enhancer-binding protein delta mediates glioma stem-like cell enrichment and ATP-binding cassette transporter ABCA1 activation for temozolomide resistance in glioblastoma

10.1038/s41420-020-00399-4 · 2021 · External reference

Quiescent human glioblastoma cancer stem cells drive tumor initiation, expansion, and recurrence following chemotherapy

10.1016/j.devcel.2021.12.007 · 2022 · External reference

Doxorubicin-polyglycerol-nanodiamond conjugates disrupt STAT3/IL-6-mediated reciprocal activation loop between glioblastoma cells and astrocytes

10.1016/j.jconrel.2020.01.044 · 2020 · External reference

PI3Kγ inhibition suppresses microglia/TAM accumulation in glioblastoma microenvironment to promote exceptional temozolomide response

10.1073/pnas.2009290118 · 2021 · External reference

TGF-β1 modulates temozolomide resistance in glioblastoma via altered microRNA processing and elevated MGMT

10.1093/neuonc/noaa198 · 2021 · External reference

Nanoparticles for immobilization and delivery of temozolomide: functional design of carriers, advances, limitations and opportunities for glioblastoma co-therapy

10.1016/j.bioadv.2026.214829 · 2026 · External reference

Biomimetic hybrid PROTAC nanovesicles block multiple DNA repair pathways to overcome temozolomide resistance against orthotopic glioblastoma

10.1002/adma.202504253 · 2025 · External reference

Nano-codelivery of temozolomide and sipd-l1 to reprogram the drug-resistant and immunosuppressive microenvironment in orthotopic glioblastoma

10.1021/acsnano.1c09794 · 2022 · External reference

A local combination therapy to inhibit gbm recurrence

10.1016/j.jconrel.2019.08.012 · 2019 · External reference

Repurposing neurological drugs for brain cancer therapeutics: a systematic approach to identify charged molecules for affinity-based local drug delivery systems

10.1016/j.ijpharm.2025.125935 · 2025 · External reference

Spatial analysis of recurrent glioblastoma reveals perivascular niche organization

10.1172/jci.insight.179853 · 2024 · External reference

Rationally designed drug delivery systems for the local treatment of resected glioblastoma

10.1016/j.addr.2021.113951 · 2021 · External reference

Glioblastoma precision therapy: from the bench to the clinic

10.1016/j.canlet.2020.01.027 · 2020 · External reference

Preventing glioblastoma relapse by igniting innate immunity through mitochondrial stress in the surgical cavity

10.1002/adma.202511351 · 2026 · External reference

Pharmacokinetics of the carmustine implant

10.2165/00003088-200241060-00002 · 2002 · External reference

The delivery of BCNU to brain tumors

10.1016/s0168-3659(99)00098-x · 1999 · External reference

Limitations of Gliadel wafers and strategies for next-generation local delivery systems for glioblastoma

10.3390/cancers18060907 · 2026 · External reference

Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial

10.1007/s00701-005-0707-z · 2006 · External reference

Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review

10.1186/s12957-016-0975-5 · 2016 · External reference

The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation

10.3310/hta11450 · 2007 · External reference

Intracranial microcapsule drug delivery device for the treatment of an experimental gliosarcoma model

10.1016/j.biomaterials.2010.12.020 · 2011 · External reference

Interstitial control-released polymer carrying a targeting small-molecule drug reduces PD-L1 and MGMT expression in recurrent high-grade gliomas with TMZ resistance

10.3390/cancers14041051 · 2022 · External reference

New approach in delivering chemotherapy: locoregional treatment for recurrent glioblastoma (rGBM)

2003 · External reference

Convection-enhanced delivery for the treatment of glioblastoma

10.1093/neuonc/nou354 · 2015 · External reference

Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma

10.1093/neuonc/nop054 · 2010 · External reference

Convection-enhanced delivery of auristatin-conjugated layer-by-layer nanoparticles for glioblastoma treatment

10.1021/jacs.4c16898 · 2025 · External reference

Convection enhanced delivery of the oncolytic adenovirus Delta24-RGD in patients with recurrent GBM: a phase I clinical trial including correlative studies

10.1158/1078-0432.ccr-21-3324 · 2022 · External reference

Convection-enhanced delivery for brain malignancies: technical parameters, formulation strategies and clinical perspectives

10.1016/j.addr.2025.115657 · 2025 · External reference

A phase I study of convection-enhanced delivery (CED) of liposomal-irinotecan using real-time magnetic resonance imaging in patients with recurrent high-grade glioma

10.1007/s11060-024-04904-y · 2025 · External reference

Chronic convection-enhanced delivery of topotecan for patients with recurrent glioblastoma: a first-in-patient, single-Centre, single-arm, phase Ib trial

10.1016/s1470-2045(22)00599-x · 2022 · External reference

Flexible, sticky, and biodegradable wireless device for drug delivery to brain tumors

10.1038/s41467-019-13198-y · 2019 · External reference

Repeated blood-brain barrier opening with a nine-emitter implantable ultrasound device in combination with carboplatin in recurrent glioblastoma: a phase I/II clinical trial

10.1038/s41467-024-45818-7 · 2024 · External reference

Repeated blood-brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase I trial

10.1016/s1470-2045(23)00112-2 · 2023 · External reference

Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience

10.1185/03007990802508180 · 2008 · External reference

Injectable hydrogels for sustained release of therapeutic agents

10.1016/j.jconrel.2017.08.006 · 2017 · External reference

Advances in injectable hydrogels based on diverse gelation methods for biomedical imaging

10.1002/smtd.202400076 · 2024 · External reference

Injectable hydrogels: in-situ tissue engineering strategies for cartilage repair and regeneration

10.1021/acsami.5c02618 · 2025 · External reference

Injectable bioresorbable conductive hydrogels for multimodal brain tumor electroimmunotherapy

10.1038/s41467-025-65785-x · 2025 · External reference

Remodeling brain pathological microenvironment to lessen cerebral ischemia injury by multifunctional injectable hydrogels

10.1016/j.jconrel.2024.03.050 · 2024 · External reference

Customized intranasal hydrogel delivering methylene blue ameliorates cognitive dysfunction against Alzheimer’s disease

10.1002/adma.202307081 · 2024 · External reference

Injectable reactive oxygen and nitrogen species-scavenging hydrogels for repairing traumatic brain injury

10.1016/j.mtbio.2025.102336 · 2025 · External reference

Encapsulated therapeutic stem cells implanted in the tumor resection cavity induce cell death in gliomas

10.1038/nn.3019 · 2011 · External reference

Overall survival in malignant glioma is significantly prolonged by neurosurgical delivery of etoposide and temozolomide from a thermo-responsive biodegradable paste

10.1158/1078-0432.ccr-18-3850 · 2019 · External reference

Injectable nanomedicine hydrogel for local chemotherapy of glioblastoma after surgical resection

10.1016/j.jconrel.2017.08.019 · 2017 · External reference

In situ chemically crosslinked injectable hydrogels for the subcutaneous delivery of trastuzumab to treat breast cancer

10.1016/j.actbio.2019.01.003 · 2019 · External reference

White-light-induced synthesis of injectable alginate-based composite hydrogels for rapid hemostasis

2023 · External reference

Injectable nano-composite hydrogels based on hyaluronic acid-chitosan derivatives for simultaneous photothermal-chemo therapy of cancer with anti-inflammatory capacity

10.1016/j.carbpol.2023.120721 · 2023 · External reference

Physically crosslinked chitosan/αβ-glycerophosphate hydrogels enhanced by surface-modified cyclodextrin: an efficient strategy for controlled drug release

2024 · External reference

An injectable biomimetic hydrogel adapting brain tissue mechanical strength for postoperative treatment of glioblastoma without anti-tumor drugs participation

10.1016/j.jconrel.2024.07.068 · 2024 · External reference

Injectable oxidized high-amylose starch hydrogel scaffold for macrophage-mediated glioblastoma therapy

10.1016/j.biomaterials.2025.123128 · 2025 · External reference

Bioprintable and injectable tio-loaded hydrogels for photothermal therapy of glioma

2025 · External reference

A daily temperature rhythm in the human brain predicts survival after brain injury

10.1093/brain/awab466 · 2022 · External reference

Penetrative and sustained drug delivery using injectable hydrogel nanocomposites for postsurgical brain tumor treatment

10.1021/acsnano.2c10094 · 2023 · External reference

STING stimulation via supramolecular prodrug hydrogel boosts innate-adaptive immune cross-talk to prevent glioblastoma recurrence

10.1126/sciadv.adx9671 · 2026 · External reference

Three-dimensional printing of chemically crosslinked gelatin hydrogels for adipose tissue engineering

10.1088/1758-5090/ab56f9 · 2020 · External reference

Assembled embedded 3D hydrogel system for asynchronous drug delivery to inhibit postoperative recurrence of malignant glioma and promote neurological recovery

10.1002/adfm.202401383 · 2024 · External reference

Development of a synthetic, injectable hydrogel to capture residual glioblastoma and glioblastoma stem-like cells with CXCL12-mediated chemotaxis

10.1002/adhm.202300671 · 2023 · External reference

Hydrogel-based implantable system for local delivery of temozolomide in postsurgical brain cancer therapy

10.1016/j.cej.2025.164175 · 2025 · External reference

Advances in nanohybrid hydrogels for wound healing: from functional mechanisms to translational prospects

10.3390/gels11070483 · 2025 · External reference

Hybrid nanoparticle-hydrogel systems for drug delivery depots and other biomedical applications

10.1021/acsnano.4c06888 · 2024 · External reference

Intracavitary spraying of nanoregulator-encased hydrogel modulates cholesterol metabolism of glioma-supportive macrophage for postoperative glioblastoma immunotherapy

10.1002/adma.202311109 · 2024 · External reference

In situ sprayed exosome-cross-linked gel as artificial lymph nodes for postoperative glioblastoma immunotherapy

10.1021/acsnano.4c02425 · 2024 · External reference

Neurosurgical application of olaparib from a thermo-responsive paste potentiates DNA damage to prolong survival in malignant glioma

10.1038/s41416-024-02878-2 · 2024 · External reference

Multi-material electrospinning: from methods to biomedical applications

2023 · External reference

Electrospinning and nanofiber technology: fundamentals, innovations, and applications

2025 · External reference

Intelligent electrospinning nanofibrous membranes for monitoring and promotion of the wound healing

2024 · External reference

Engineering of nanofibers embedded with targeted nanoparticles breaks redox levers for glioblastoma therapy

10.1002/adfm.202413518 · 2025 · External reference

Time-staggered chemo-immunotherapy via engineered nanofiber resists postoperative dynamic immunosuppression in glioblastoma

10.1038/s41467-026-75065-x · 2026 · External reference

NIR-II-triggered composite nanofibers to simultaneously achieve intracranial hemostasis, killing superbug and residual cancer cells in brain tumor resection surgery

10.1007/s42765-022-00210-2 · 2023 · External reference

Locally implantable nanofibre meshes by sustained release of temozolomide for combined thermo-chemotherapy to treat glioblastoma

10.1039/d3nj00534h · 2023 · External reference

Advanced fabrication for electrospun three-dimensional nanofiber aerogels and scaffolds

2020 · External reference

The impacts of the sterilization method and the electrospinning conditions of nanofibrous biodegradable layers on their degradation and hemocompatibility behavior

10.3390/polym16081029 · 2024 · External reference

Progress in the design and development of “fast-dissolving” electrospun nanofibers based drug delivery systems-a systematic review

10.1016/j.jconrel.2020.07.038 · 2020 · External reference

3D bioprinting models for glioblastoma: from scaffold design to therapeutic application

10.1002/adma.202501994 · 2025 · External reference

Three-dimensional printing of curcumin-loaded biodegradable and flexible scaffold for intracranial therapy of glioblastoma multiforme

10.3390/pharmaceutics13040471 · 2021 · External reference

Conformable hierarchically engineered polymeric micromeshes enabling combinatorial therapies in brain tumours

10.1038/s41565-021-00879-3 · 2021 · External reference

A self-cascading catalytic therapy and antigen capture scaffold-mediated t cells augments for postoperative brain immunotherapy

10.1002/smll.202406178 · 2024 · External reference

The surgical management of diffuse gliomas: current state of neurosurgical management and future directions

10.1093/neuonc/noad133 · 2023 · External reference

Emerging 3D printing technologies for drug delivery devices: current status and future perspective

10.1016/j.addr.2021.04.019 · 2021 · External reference

Translating 3D printed pharmaceuticals: from hype to real-world clinical applications

10.1016/j.addr.2021.05.003 · 2021 · External reference

Dissolvable polymer microneedles for drug delivery and diagnostics

10.1016/j.jconrel.2022.04.043 · 2022 · External reference

Intranasal and intravenous sequential administration of survivin peptide-CPG nanovaccines elicits potent immunity toward glioblastoma

10.1002/adma.202420630 · 2025 · External reference

Low-intensity pulsed ultrasound-mediated nose-to-brain co-delivery of β-blockers and APD-l1 enhances glioblastoma immunotherapy

10.1038/s41467-026-76103-4 · 2026 · External reference

Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system

10.1002/jps.21604 · 2009 · External reference

Left-right difference in brain pharmacokinetics following nasal administration via one-site nostrils

10.1016/j.xphs.2024.05.003 · 2024 · External reference

Nose-to-brain drug delivery: challenges and progress towards brain targeting in the treatment of neurological disorders

10.1016/j.jddst.2023.104756 · 2023 · External reference

Nose-to-brain delivery of biomimetic nanoparticles for glioblastoma targeted therapy

10.1021/acsami.4c16837 · 2025 · External reference

Nasal administration of a temozolomide-loaded thermoresponsive nanoemulsion reduces tumor growth in a preclinical glioblastoma model

10.1016/j.jconrel.2023.01.070 · 2023 · External reference

Detection of perillyl alcohol and its metabolite perillic acid in postsurgical glioblastoma tissue after intranasal administration of NEO100: illustrative case

10.3171/case22215 · 2022 · External reference

Phase I trial of intranasal NEO100, highly purified perillyl alcohol, in adult patients with recurrent glioblastoma

10.1093/noajnl/vdab005 · 2021 · External reference

Receptor-mediated nose-to-brain delivery of drug combination-loaded polymeric nanocarriers for the treatment of glioblastoma- current progress and future perspectives part I: receptor-mediated nose-to-brain delivery approaches for glioblastoma

10.1080/17425247.2025.2578384 · 2026 · External reference

Drug-metabolizing enzymes and efflux transporters in nasal epithelium: influence on the bioavailability of intranasally administered drugs

10.2174/1389200217666160406120509 · 2016 · External reference

Nose-to-brain delivery: exploring newer domains for glioblastoma multiforme management

10.1007/s13346-020-00747-y · 2020 · External reference

Chitosan-PLGA mucoadhesive nanoparticles for gemcitabine repurposing for glioblastoma therapy

10.1016/j.ejpb.2024.114326 · 2024 · External reference

Intranasal delivery to the central nervous system: mechanisms and experimental considerations

10.1002/jps.21924 · 2010 · External reference

Regulating protein corona on nanovesicles by glycosylated polyhydroxy polymer modification for efficient drug delivery

10.1038/s41467-024-45254-7 · 2024 · External reference

Rediscovery of mononuclear phagocyte system blockade for nanoparticle drug delivery

10.1038/s41467-024-48838-5 · 2024 · External reference

Beyond the blood-brain barrier: the fate of transcytosed therapeutics

10.1016/j.tips.2025.08.006 · 2025 · External reference

Modulation of blood-tumor barrier transcriptional programs improves intratumoral drug delivery and potentiates chemotherapy in GBM

10.1126/sciadv.adr1481 · 2025 · External reference

Rational design of siRNA-based delivery systems for effective treatment of brain diseases

2024 · External reference

Modulation of blood-brain tumor barrier for delivery of magnetic hyperthermia to brain cancer

10.1016/j.jconrel.2023.01.072 · 2023 · External reference

Synchronous disintegration of ferroptosis defense axis via engineered exosome-conjugated magnetic nanoparticles for glioblastoma therapy

2022 · External reference

Targeting glioblastoma: advances in drug delivery and novel therapeutic approaches

10.1002/adtp.202000124 · 2021 · External reference

Lipid nanoparticle formulation for gene editing and RNA-based therapies for glioblastoma

10.1093/neuonc/noaf162 · 2025 · External reference

Sphingosine 1-phosphate liposomes for targeted nitric oxide delivery to mediate anticancer effects against brain glioma tumors

10.1002/adma.202101701 · 2021 · External reference

Enhanced BBB and BBTB penetration and improved anti-glioma behavior of bortezomib through dual-targeting nanostructured lipid carriers

10.1016/j.jconrel.2022.03.019 · 2022 · External reference

Chemotherapeutic nanoparticles for glioblastoma

10.3389/fonc.2025.1641752 · 2025 · External reference

Gint4.T-siHDGF chimera-capped mesoporous silica nanoparticles encapsulating temozolomide for synergistic glioblastoma therapy

10.1016/j.biomaterials.2024.122479 · 2024 · External reference

Overcoming the blood-brain tumor barrier with docetaxel-loaded mesoporous silica nanoparticles for treatment of temozolomide-resistant glioblastoma

10.1021/acsami.4c04289 · 2024 · External reference

A biodegradable nanocapsule for through-skull NIR-II fluorescence imaging/magnetic resonance imaging and selectively enhanced radio-chemotherapy for orthotopic glioma

10.1016/j.nantod.2022.101619 · 2022 · External reference

Engineered apoptotic bodies hitchhiking across the blood-brain barrier achieved a combined photothermal-chemotherapeutic effect against glioma

10.7150/thno.80632 · 2023 · External reference

Polymeric nanoparticles for drug delivery in glioblastoma: state of the art and future perspectives

10.1016/j.jconrel.2022.07.023 · 2022 · External reference

Applications of polymeric nanoparticles in drug delivery for glioblastoma

10.3389/fphar.2024.1519479 · 2025 · External reference

Polymer degradation and drug delivery in plga-based drug-polymer applications: a review of experiments and theories

10.1002/jbm.b.33648 · 2016 · External reference

Nanocarrier-based drug combination therapy for glioblastoma

10.7150/thno.38147 · 2020 · External reference

Spatiotemporal heterogeneity in multiparametric physiologic mri is associated with patient outcomes in idh-wildtype glioblastoma

10.1158/1078-0432.ccr-20-2156 · 2020 · External reference

A predictive microfluidic model of human glioblastoma to assess trafficking of blood-brain barrier-penetrant nanoparticles

10.1073/pnas.2118697119 · 2022 · External reference

An iRGD-conjugated prodrug micelle with blood-brain-barrier penetrability for anti-glioma therapy

10.1016/j.biomaterials.2019.119666 · 2020 · External reference

Semiconducting polymer nanotransducers reinvigorate antitumor immunity through amplifying radio/chemodynamic therapy in orthotopic glioma

10.1002/adhm.202504381 · 2026 · External reference

New avenues for cancer immunotherapy: cell-mediated drug delivery systems

10.1016/j.jconrel.2024.09.037 · 2024 · External reference

Cell-mediated nanoparticle delivery systems: towards precision nanomedicine

10.1007/s13346-024-01591-0 · 2024 · External reference

Theoretical basis, state and challenges of living cell-based drug delivery systems

10.7150/thno.99257 · 2024 · External reference

Neutrophils as emerging therapeutic targets

10.1038/s41573-019-0054-z · 2020 · External reference

Neutrophils in cancer: heterogeneous and multifaceted

10.1038/s41577-021-00571-6 · 2021 · External reference

Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence

10.1038/nnano.2017.54 · 2017 · External reference

MR imaging tracking of inflammation-activatable engineered neutrophils for targeted therapy of surgically treated glioma

10.1038/s41467-018-07250-6 · 2018 · External reference

Mesenchymal stem cells as therapeutic vehicles for glioma

10.1038/s41417-024-00775-7 · 2024 · External reference

To explore the stem cells homing to GBM: the rise to the occasion

10.3390/biomedicines10050986 · 2022 · External reference

Tropism of mesenchymal stem cell toward CD133+ stem cell of glioblastoma in vitro and promote tumor proliferation in vivo

10.1186/s13287-018-1049-0 · 2018 · External reference

Ionizing radiation augments glioma tropism of mesenchymal stem cells[J]

10.3171/2016.9.jns16278 · 2017 · External reference

Bridging process diversity in cell therapies toward standardization of manufacturing workflows

10.1016/j.jcyt.2025.102041 · 2026 · External reference

Managing allorejection in off-the-shelf car-engineered cell therapies

10.1016/j.ymthe.2024.11.035 · 2024 · External reference

Potency testing of cell and gene therapy products

10.3389/fmed.2023.1190016 · 2023 · External reference

Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches

10.1002/jev2.12404 · 2024 · External reference

Extracellular-vesicle-based drug delivery systems for enhanced antitumor therapies through modulating the cancer-immunity cycle

10.1002/adma.202201054 · 2022 · External reference

Tumor-targeted exosomes for delivery of anticancer drugs

10.1016/j.canlet.2023.216093 · 2023 · External reference

Inflammatory tumor microenvironment responsive neutrophil exosomes-based drug delivery system for targeted glioma therapy

10.1016/j.biomaterials.2021.120784 · 2021 · External reference

Malignant glioma therapy by vaccination with irradiated C6 cell-derived microvesicles promotes an antitumoral immune response

10.1016/j.ymthe.2019.05.016 · 2019 · External reference

Heterogeneity of mesenchymal stem cell-derived extracellular vesicles is highly impacted by the tissue/cell source and culture conditions

10.1186/s13578-022-00786-7 · 2022 · External reference

Comparative analysis of tangential flow filtration and ultracentrifugation, both combined with subsequent size exclusion chromatography, for the isolation of small extracellular vesicles

10.1002/jev2.12266 · 2022 · External reference

Extracellular vesicles as a next-generation drug delivery platform

10.1038/s41565-021-00931-2 · 2021 · External reference

Regulatory challenges and opportunities for cell-derived extracellular vesicles in pharmaceutical development: a European and global perspective

10.1002/jev2.70332 · 2026 · External reference

Manufacturing, quality control, and GLP-grade preclinical study of nebulized allogenic adipose mesenchymal stromal cells-derived extracellular vesicles

10.1186/s13287-024-03708-1 · 2024 · External reference